三项多中心、随机、双盲、安慰剂对照研究评估乌司奴单抗治疗中轴型脊柱关节炎的疗效与安全性
三项随机双盲安慰剂对照研究分别纳入放射学阳性中轴型脊柱关节炎抗肿瘤坏死因子初治患者、抗肿瘤坏死因子应答不足或不耐受患者及放射学阴性中轴型脊柱关节炎患者,评估乌司奴单抗45 mg或90 mg皮下注射的疗效与安全性。研究1第24周分析未达到主要和主要次要终点并终止,研究2和研究3在未完全入组前提前终止;三项研究中乌司奴单抗各剂量组均未在关键疗效终点上显示优于安慰剂的临床意义改善,安全性特征与既往其他适应症研究一致。
要点
- 研究1主要及主要次要终点均未达到,研究因此终止。
- 研究2和研究3因研究1结果在未完全入组前提前终止。
- 三项研究中乌司奴单抗各剂量组关键疗效终点均未优于安慰剂。
核心结论
- 三项安慰剂对照试验中,乌司奴单抗治疗中轴型脊柱关节炎的疗效未获证实。
- 安全性特征与其他适应症研究一致。
研究设计与样本
- 三项多中心、随机、双盲、安慰剂对照研究,患者按1:1:1随机接受乌司奴单抗45 mg、90 mg或安慰剂皮下注射至24周。
- 研究1纳入放射学阳性中轴型脊柱关节炎抗肿瘤坏死因子初治患者,研究2纳入抗肿瘤坏死因子应答不足或不耐受的放射学阳性中轴型脊柱关节炎患者,研究3纳入放射学阴性中轴型脊柱关节炎患者。
- 24周后安慰剂组患者再随机接受乌司奴单抗45 mg或90 mg。
- 研究1和研究2主要终点为达到ASAS40应答的患者比例,研究3主要终点为达到ASAS20应答的患者比例。
- 研究1第24周分析为预先计划,用于决定研究2和研究3是否继续。
主要发现
- 研究1主要和主要次要终点均未达到,研究被终止。
- 研究2和研究3在未完全入组前提前终止。
- 三项研究中乌司奴单抗各剂量组在关键疗效终点上均未显示优于安慰剂的临床意义改善。
- 乌司奴单抗组不良事件发生比例与既往研究一致。
关键数值与推荐
- 研究1和研究2主要终点为ASAS40应答患者比例,研究3主要终点为ASAS20应答患者比例。
- 乌司奴单抗给药为皮下注射45 mg或90 mg,安慰剂对照至24周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究1因主要和主要次要终点未达到而终止。
- 研究2和研究3在未完全入组前提前终止。
- 原文结论指出乌司奴单抗在中轴型脊柱关节炎治疗中的疗效未获证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo-controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients with radiographic axial SpA (anti-tumor necrosis factor [anti-TNF]-naive patients and patients with inadequate response or intolerance to anti-TNF, respectively); study 3 patients had nonradiographic axial SpA. METHODS: In all 3 studies, patients were randomly assigned (1:1:1) to receive subcutaneous ustekinumab at 45 mg or 90 mg or placebo up to 24 weeks, after which placebo-treated patients were rerandomized to receive ustekinumab at 45 mg or 90 mg. The primary end point in studies 1 and 2 was the proportion of patients who met the Assessment of SpondyloArthritis international Society criteria for 40% improvement in disease activity (achieved an ASAS40 response). The primary end point in study 3 was the proportion of patients who achieved an ASAS20 response. Other disease activity and safety measures were also evaluated. A week 24 analysis of study 1 was preplanned to determine continuation of studies 2 and 3. RESULTS: For study 1, the primary and major secondary end points were not met, and the study was discontinued. As a result, studies 2 and 3 were prematurely discontinued before they were fully enrolled. For all 3 studies, neither ustekinumab dose group demonstrated clinically meaningful improvement over placebo on key efficacy end points. The proportion of patients experiencing adverse events in the ustekinumab groups was consistent with that in previous studies. CONCLUSION: In these 3 placebo-controlled trials, efficacy of ustekinumab in the treatment of axial SpA was not demonstrated. The safety profile was consistent with that of studies in other indications.
引用
- Deodhar A, Gensler LS, Sieper J, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol. 2018. PMID: 30225992. doi:10.1002/art.40728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。